Cocrystal Pharma Cuts Q1 Losses 42% Amid Antiviral Progress

Cocrystal Pharma reported a reduced net loss of $2.3 million in Q1 2025, down from $4.0 million the previous year, alongside a significant 53% decrease in R&D expenses due to personnel cuts and adjusted clinical timelines. Their lead drug candidate, CDI-988, an oral pan-viral protease inhibitor targeting norovirus strains, showed promising safety and broad-spectrum antiviral activity, with plans for a U.S. human challenge study underway. The company also continues advancing its influenza drug CC-42344 in Phase 2a trials despite delays caused by low infection rates, maintaining focus on large markets including influenza, norovirus, and coronavirus therapeutics. Cocrystal leverages a novel structure-based drug discovery platform that targets conserved viral enzyme regions, enhancing efficacy against viral mutations while reducing side effects and accelerating candidate identification. Meanwhile, Coya Therapeutics maintained a positive analyst outlook with a 'Buy' rating and an average price target of around $17, implying nearly 192% upside from current prices, supported by strong cash reserves of $35.5 million and ongoing clinical progress in neuroinflammation and systemic inflammation treatments. Despite a net loss of $7.3 million and challenges in profitability, Coya's pipeline advancements and financial stability underpin optimistic market sentiment and an 'Outperform' brokerage consensus.